Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Brain and Behavior Research Fund, and was created with funding from the U.S. National Institute of Mental Health.
Printable version  
SZGene - Gene overview of all published SZ-association studies for HTR2A    
Back Search Methods Disclaimer Credits
 Gene: HTR2A  (HTR2; 5-HT2A)  Entrez Gene    View on AlzGene   View on PDGene
 Protein: 5-hydroxytryptamine receptor 2A  (5-HT2 receptor; serotonin receptor 2A)  ProteinLink
 Chromosome: 13   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 22 October 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      SZ Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result Comment
 Caucasian
Anttila, 2007
 Finland CL  1  (detail)  94
(51%)		IV30 + 9.9
(-)		45.9 + 10.9
(-)		392
(46%)		44.4 + 11.1
(-)		Negative
Arranz, 1995
 UK CL  1  (detail)  149
(53%)		IIIR--99
(-)		-Negative
Arranz, 1996a
 UK CL  1  (detail)  153
(-)		IIIR--178
(-)		-Negative
Arranz, 1996b
 UK CL  1  (detail)  74
(-)		IIIR--183
(-)		-Negative
Arranz, 1998
 UK CL  1  (detail)  160
(-)		IIIR--178
(-)		-Negative
Arranz, 1998
 Overlaps with
Arranz, 1996a		 CL  1  (detail)  160
(-)		IIIR--178
(-)		-n.a.
Baritaki, 2004
 Greece CL  1  (detail)  114
(41%)		IV25.5 + 9.2
(14-60)		50.6 + 13.3
(-)		192
(39%)		45.1 + 8.7
(-)		Positive
Bertola, 2007
 Spain CL  1  (detail)  246
(-)		IV--315
(-)		-Negative
Betcheva, 2009
 Bulgaria CL  2  (detail)  185
(-)		IV--184
(-)		-Negative
Boke, 2007
 Turkey CL  1  (detail)  127
(41%)		IV-39.6 + 9
(-)		100
(38%)		45.7 + 15
(-)		Negative
Czerski, 2003
 Poland CL  1  (detail)  235
(40%)		M22.9 + 5.8
(-)		30.6 + 10.5
(-)		344
(60%)		41 + 11
(-)		Negative
Domingeuz, 2006
 Spain CL  27  (detail)  260
(35%)		IV--354
(55%)		-Trend
Erdmann, 1996
 Germany CL  4  (detail)  323
(-)		IIIR--253
(-)		-Positive
Golimbet, 2002
 Overlaps with
Golimbet, 2007		 CL  1  (detail)  375
(55%)		10--157
(59%)		32.6 + 13.8
(-)		n.a.
Golimbet, 2007
 Russia CL  1  (detail)  919
(59%)		1026.1 + 10.3
(-)		38.2 + 14.1
(-)		500
(51%)		37.7 + 13.7
(-)		Positive
Hawi, 1997
 Ireland CL  1  (detail)  247
(-)		U--249
(-)		-Negative
He, 1999
 UK CL  1  (detail)  253
(-)		IIIR--244
(46%)		-Negative
Herken, 2003a
 Turkey CL  2  (detail)  143
(35%)		IV-32.3 + 9.1
(-)		79
(-)		-Negative
Herken, 2003b
 Overlaps with
Herken, 2003a		 CL  1  (detail)  141
(35%)		IV-34.1 + 9.8
(-)		79
(35%)		30.5 + 6.1
(-)		n.a.
Jonsson, 1996
 Sweden CL  1  (detail)  118
(-)		IIIR--99
(-)		-Negative
Joober, 1999
 Canada CL  1  (detail)  102
(26%)		IV--90
(47%)		44.6 + 12.8
(-)		Trend
Melkersson, 2009
 Sweden CL  4  (detail)  94
(50%)		IV26
(-)		44 + 9
(-)		57
(74%)		45 + 11
(-)		Positive
Penas-Lledo, 2007
 Spain CL  2  (detail)  114
(11%)		IV-55 + 12
(-)		142
(50%)		30 + 11
(-)		Positive
Rao, 1998
 Overlaps with
Nimgaonkar, 1996		 CL  1  (detail)  80
(40%)		IV-37.4 + 10
(-)		127
(66%)		30 + 10.3
(-)		n.a.
Saiz, 2007
 Spain CL  2  (detail)  227
(40%)		IV-35.7 + 11.7
(-)		420
(49%)		40.6 + 11.3
(-)		Negative
Sanders, 2008
 USA, Australia CL  30  (detail)  1870
(31%)		IV--2002
(53%)		-Negative
Spurlock, 1998
 UK CL  1  (detail)  115
(32%)		IIIR-46 + 12
(-)		115
(32%)		45 + 12
(-)		Negative
Vaquero Lorenzo, 2006
 Spain CL  1  (detail)  188
(50%)		IV-36 + 11.4
(-)		440
(42%)		43.1 + 14.1
(-)		Positive
Verga, 1997
 Overlaps with
Williams, 1996		 CL  1  (detail)  100
(40%)		IIIR23.1 + 7.5
(-)		50.7 + 16.7
(-)		103
(50%)		38.1 + 12.1
(-)		n.a.
Virgos, 2001
 Spain CL  1  (detail)  262
(40%)		9-61.4
(19-90)		278
(39%)		54.2
(21-90)		Negative
Williams, 1996
 Austria CL  1  (detail)  72
(-)		IIIR--57
(-)		-Positive
Williams, 1996
 France CL  1  (detail)  101
(-)		IIIR--122
(-)		-Positive
Williams, 1996
 Germany CL  1  (detail)  100
(-)		IIIR--100
(-)		-Positive
Williams, 1996
 Ireland CL  1  (detail)  37
(-)		IIIR--89
(-)		-Positive
Williams, 1996
 Italy CL  1  (detail)  100
(-)		IIIR--103
(-)		-Positive
Williams, 1996
 Sweden CL  1  (detail)  67
(-)		IIIR--74
(-)		-Positive
Williams, 1996
 UK CL  1  (detail)  94
(-)		IIIR--94
(-)		-Positive
 African Descent
Rao, 1998
 Overlaps with
Nimgaonkar, 1996		 CL  1  (detail)  47
(43%)		IV-35.2 + 9.3
(-)		37
(57%)		30 + 8
(-)		n.a.
 Asian
Chen, 1997
 Taiwan CL  1  (detail)  177
(46%)		IIIR-47
(-)		98
(51%)		45
(-)		Negative
Chen, 2001
 China CL  1  (detail)  471
(29%)		IV-42.3 + 10.2
(18-60)		523
(41%)		41.9 + 9.7
(-)		Negative
He, 1999
 China CL  1  (detail)  202
(-)		IIIR--202
(55%)		-Negative
Inayama, 1996
 Japan CL  1  (detail)  62
(42%)		IIIR26.5 + 7.5
(-)		45 + 11.8
(-)		96
(60%)		37.1 + 14.4
(-)		Positive
Ishigaki, 1996
 Japan CL  1  (detail)  158
(49%)		IV26 + 9.7
(-)		44.6 + 16.2
(-)		150
(57%)		37 + 15.4
(-)		Negative
Kim, 1999
 Korea CL  1  (detail)  127
(36%)		IV27 + 8.5
(-)		38 + 11.4
(-)		100
(42%)		36 + 7.8
(-)		Negative
Lin, 1999
 China CL  1  (detail)  97
(-)		IV--101
(-)		-Negative
Ohara, 1999
 Japan CL  1  (detail)  119
(48%)		IV25.3 + 9.2
(-)		43.7 + 15.8
(-)		106
(-)		-Negative
Pae, 2005
 Korea CL  1  (detail)  111
(52%)		IV-30.3 + 9.4
(-)		172
(53%)		25 + 9.9
(-)		Negative
Sasaki, 1996
 Japan CL  1  (detail)  121
(-)		IIIR--162
(-)		-Negative
Shinkai, 1998
 Japan CL  1  (detail)  106
(41%)		IV-54.5 + 12.2
(16-74)		109
(65%)		54.6 + 6.8
(45-72)		Negative
Tan, 2001
 Overlaps with
Tan, 2002		 CL  1  (detail)  221
(23%)		IV-51.5 + 9
(-)		97
(34%)		-n.a.
Tan, 2002
 China CL  1  (detail)  286
(-)		IV--94
(-)		-Negative
Tay, 1997
 Singapore CL  1  (detail)  101
(0%)		9--103
(0%)		-Positive
Tsunoka, 2010
 Japan CL  2  (detail)  738
(46%)		10-41.2 + 13.8
(-)		802
(56%)		37.6 + 14.3
(-)		Negative
Yoshihara, 2000
 Japan CL  1  (detail)  31
(-)		U--55
(-)		-Negative
Zhang, 2004
 China (I) CL  1  (detail)  158
(40%)		IV26.7 + 7.5
(-)		55.2 + 10.2
(29-79)		173
(57%)		56.7 + 10.6
(25-92)		Negative
Zhang, 2004
 China (II) CL  1  (detail)  133
(46%)		IV25.2 + 7.3
(-)		40.3 + 10.4
(28-65)		134
(40%)		41 + 9.5
(24-82)		Negative
 Other/Mixed
Araga, 2002
 India CL  1  (detail)  100
(39%)		IV--100
(-)		-Positive
Correa, 2007
 Brazil CL  1  (detail)  129
(39%)		IV--85
(47%)		-Negative
Haider, 2002
 Kuwait CL  1  (detail)  80
(25%)		1042.2
(-)		41.9
(19-69)		109
(-)		-Negative
Kouzmenko, 1999
 Australia CL  1  (detail)  58
(-)		IIIR--64
(-)		-Negative
Nimgaonkar, 1996
 USA CL  1  (detail)  174
(46%)		IIIR-35.9 + 9.9
(-)		239
(63%)		31.1 + 10.5
(-)		Negative
Segman, 2001
 Israel CL  3  (detail)  121
(-)		IV--96
(46%)		-Trend
Semwal, 2002
 India CL  2  (detail)  536
(44%)		IV-22.8 + 7
(-)		936
(47%)		32.9 + 12.7
(-)		Positive
Tee, 2010
 Malaysia CL  1  (detail)  289
(35%)		M-45.5 + 13.6
(-)		130
(44%)		36.8 + 11.2
(-)		Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result Comment
 Caucasian
De Luca, 2007
 Canada  1  (detail)  8181
(-)		IV--162
(50%)		-Negative
Fallin, 2005
 USA  9  (detail)  263274
(26%)		IV19.5 + 4.5
(-)		-548
(50%)		-Negative
Golimbet, 2002
 Russia  1  (detail)   375
(55%)		10--104
(42%)		43.7 + 14.7
(-)		Negative
Golimbet, 2007
 Russia  1  (detail)  134919
(59%)		1026.1 + 10.3
(-)		38.2 + 14.1
(-)		330
(51%)		46.3 + 13.1
(-)		Positive
Spurlock, 1998
 Overlaps with
Spurlock, 1998		  1  (detail)  6363
(32%)		IIIR-35 + 9
(-)		126
(50%)		-n.a.
Verga, 1997
 Italy  1  (detail)  6767
(-)		IIIR--134
(50%)		-Negative
Wei, 2005
 UK  1  (detail)  124124
(31%)		U-29.3 + 7
(-)		248
(50%)		-Negative
 Asian
He, 1999
 China  1  (detail)  112112
(-)		IV--224
(50%)		-Negative
 Other/Mixed
Benmesaoud, 2008
 Algeria  1  (detail)  100-IV----Positive
Fanous, 2004
 USA  2  (detail)   651
(-)		IIIR--709
(-)		-Negative
Malhotra, 1996
 USA  1  (detail)  5252
(-)		IIIR--104
(50%)		-Negative
Semwal, 2001
 India  2  (detail)  179179
(42%)		IV22.1 + 6.3
(-)		---Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis ->  "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Research Participants
Collaborators
Copyright © 2005-2024 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright